Xinkang^® Lacosamide Oral Solution is another new member of Qingfeng Pharmaceutical's antiepileptic drug family, following the launch of lacosamide tablets and injection. It was approved for market in August 2022 as a Class 4 chemical drug and is clinically used as an adjunctive treatment for partial-onset epilepsy in patients aged 4 and above. Its unique slow-sodium mechanism improves both efficacy and safety. It effectively controls seizures without affecting the normal brain function related to electrical activity, offering a superior option over current fast-sodium channel blockers. As a new formulation, Xinkang® Lacosamide Oral Solution offers precise dosing for pediatric patients and provides an alternative formulation for patients who have difficulty swallowing tablets. It solves medication issues for patients with choking or swallowing difficulties. This innovation promises to broaden treatment options and offer a more comprehensive solution for patients with focal epilepsy, bringing hope to patients and their families.